Hypermarcas (OTCMKTS:HYPMY) Sees Significant Growth in Short Interest

Hypermarcas (OTCMKTS:HYPMY) was the target of a significant growth in short interest in October. As of October 30th, there was short interest totaling 8,208 shares, a growth of 390.0% from the October 15th total of 1,675 shares. Based on an average trading volume of 84,726 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are short sold.

Hypermarcas Stock Down 1.7%

Shares of OTCMKTS HYPMY traded down $0.07 during midday trading on Thursday, hitting $4.01. The stock had a trading volume of 63,816 shares, compared to its average volume of 46,670. The business’s 50 day moving average is $4.63 and its 200-day moving average is $4.41. The company has a market cap of $2.82 billion, a P/E ratio of 8.02 and a beta of 0.78. Hypermarcas has a 52 week low of $3.39 and a 52 week high of $5.77. The company has a quick ratio of 1.26, a current ratio of 1.86 and a debt-to-equity ratio of 0.50.

Hypermarcas (OTCMKTS:HYPMY) last released its quarterly earnings data on Wednesday, November 11th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. The business had revenue of $473.13 million for the quarter, compared to analysts’ expectations of $450.75 million. As a group, analysts predict that Hypermarcas will post 0.50 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group upgraded Hypermarcas to a “strong-buy” rating in a report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Buy”.

Hypermarcas Company Profile

Hypermarcas was a Brazilian consumer-products and pharmaceutical company that later adopted the name Hypera Pharma. The company refocused its operations on pharmaceuticals after divesting a number of businesses in other consumer-goods categories. Today, Hypera Pharma develops, manufactures and markets medicines in Brazil, including prescription drugs, over-the-counter products and branded generics. Its portfolio also includes vitamins and supplements, and it sells products under brands such as Neo Química and Mantecorp.